Alprazolam or lorazepam are the preferred benzodiazepines for acute panic attacks
For rapid relief of an acute panic attack, alprazolam is the best-studied and most effective benzodiazepine, with lorazepam as an excellent alternative. Both medications provide fast onset of action and have the strongest evidence base for panic disorder treatment.
Primary Recommendation
Alprazolam has the most robust evidence for panic disorder, with multiple controlled trials demonstrating superior efficacy in blocking panic attacks compared to placebo 1, 2, 3. It ranks highest among benzodiazepines for both effectiveness and tolerability in network meta-analysis 3. The typical starting dose for acute panic is 0.25-0.5 mg orally, which can be repeated as needed 4.
Lorazepam is equally effective and offers practical advantages 5. It can be administered via multiple routes (oral, sublingual, IV, or subcutaneous), making it versatile for different clinical scenarios 6. The typical dose is 0.5-1 mg orally or sublingually for acute panic 6.
Evidence Supporting This Choice
The 2023 Cochrane network meta-analysis of 70 trials (N=10,118) found that alprazolam and diazepam ranked as the most effective benzodiazepines for panic disorder response, with alprazolam also ranking highest for tolerability (lowest dropout rates) 3. Clonazepam showed strong efficacy but is less ideal for acute attacks due to slower onset.
Direct comparison studies confirm that alprazolam and lorazepam demonstrate similar efficacy in reducing panic attacks and phobic behavior, though both require approximately double the doses used for generalized anxiety 5. A 1996 placebo-controlled trial (N=241) showed over 60% of patients taking either diazepam or alprazolam achieved at least moderate improvement versus less than 30% with placebo 7.
Practical Considerations
Onset of action matters for acute panic:
- Alprazolam: Rapid onset (15-30 minutes orally)
- Lorazepam: Intermediate onset (20-40 minutes orally, faster sublingually)
- Both provide relief within the timeframe of a typical panic attack (peaks within 10 minutes, resolves within 20-30 minutes)
Route flexibility favors lorazepam when oral administration is difficult. The sublingual route bypasses first-pass metabolism and may provide faster relief in highly anxious patients who cannot swallow pills 6.
Critical Warnings
Avoid in these populations:
- Severe pulmonary insufficiency (risk of respiratory depression) 6
- Severe liver disease (impaired metabolism) 6
- Myasthenia gravis (worsens muscle weakness) 6
- Pregnancy (teratogenic risk)
- Active benzodiazepine dependence (worsens addiction)
Dose adjustments required:
- Elderly patients: Start with 0.25 mg alprazolam or 0.25-0.5 mg lorazepam 6
- Frail patients or COPD: Use lower doses due to increased sensitivity 6
- Concurrent CNS depressants: Reduce dose by 50% to avoid oversedation
Long-Term Perspective
While benzodiazepines provide rapid relief for acute panic attacks, they should not be first-line for ongoing panic disorder treatment 8, 9. The 2019 Lancet Psychiatry review found that approximately 50% of patients prescribed benzodiazepines in England were treated continuously for at least 12 months, a practice not recommended by guidelines 8.
For sustained treatment beyond 2-4 weeks, transition to SSRIs (particularly paroxetine or fluoxetine) or SNRIs (venlafaxine), which have comparable long-term efficacy without dependence risk 3. The 2023 Cochrane review emphasizes that benzodiazepine studies only examined short-term efficacy and did not address long-term risks of dependency and withdrawal 10.
Withdrawal risk is substantial: Alprazolam discontinuation is particularly difficult and associated with serious rebound and withdrawal symptoms 2, 11. If benzodiazepines are used beyond acute treatment, gradual tapering over weeks to months is mandatory to prevent potentially life-threatening withdrawal 8, 9, 11.
Alternative Benzodiazepines
Diazepam showed equal efficacy to alprazolam in controlled trials 7 and ranks highly in network meta-analysis 3, but its longer half-life makes it less ideal for acute panic attacks where rapid offset is desirable. It may be preferable for patients requiring less frequent dosing or those at risk for rebound anxiety.
Clonazepam demonstrated strong efficacy in reducing panic frequency 2, 3 and permits less frequent dosing due to its long half-life 2, but approximately 20% of patients experience unacceptable sedation 2. It is better suited for maintenance treatment than acute attacks.